Mercado PD-1 inhibitor approved by the US FDA for the treatment of cervical cancer patients
胡胡胡美丽_ss
发表于 2024-1-14 13:01:42
286
0
0
On January 14th, Merck announced on January 12th local time that the US Food and Drug Administration (FDA) has approved Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (CRT) for the treatment of stage III-IVA cervical cancer patients as defined by the International Federation of Obstetrics and Gynecology (FIGO) 2014.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Tesla surged last night! Bank of America raises Tesla's 12-month target price to $400 and maintains buy rating
- Weekly Outlook | US CPI may shake expectations of Fed interest rate cuts! Oracle and Broadcom announce their performance, will it affect the subsequent trend of AI concept stocks?
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- The US warehouse strike poses challenges to Amazon's holiday shopping season operations
- Sanofi's BTK inhibitor is declared for market in China
